共 50 条
- [21] Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology settingFRONTIERS IN ONCOLOGY, 2024, 14Gadgeel, Shirish M.Rai, PragyaAnnavarapu, SrinivasAlam, SartajGoldschmidt, Jerome H.West, HowardSantorelli, MelissaMartins, Renata Eiras
- [22] Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up DataCANCERS, 2022, 14 (04)Velcheti, VamsidharHu, XiaohanLi, YeranEl-Osta, HazemPietanza, M. CatherineBurke, Thomas
- [23] Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world dataONCOIMMUNOLOGY, 2021, 10 (01):Dudnik, ElizabethMoskovitz, MorRottenberg, YakirLobachov, AnastasiyaMandelboim, RinatShochat, TzippyUrban, DamienWollner, MiraNechushtan, HovavRotem, OferZer, AlonaDaher, SamehBar, Jair
- [24] Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%FRONTIERS IN PHARMACOLOGY, 2022, 12Liu, QiaoZhou, ZhenLuo, XiaYi, LidanPeng, LiubaoWan, XiaominTan, ChongqingZeng, Xiaohui
- [25] PD-L1 TPS ANALYSIS IN REAL-WORLD CLINICAL PRACTICE: EVALUATION OF SPECIMENS OBTAINED BY RESPIRATORY ENDOSCOPIC BIOPSYRESPIROLOGY, 2017, 22 : 74 - 74Tanaka, MidoriHorinouchi, HidehitoMatsumoto, YujiNakai, ToshiyukiTsuchida, TakaakiMurakami, ShujiGoto, YasushiKanda, ShintaroFujiwara, YutakaYamamoto, NoboruMotoi, NorikoOhe, Yuichiro
- [26] Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical OutcomesCLINICAL LUNG CANCER, 2020, 21 (06) : 498 - +Cortellini, AlessioFriedlaender, AlexBanna, Giuseppe L.Porzio, GiampieroBersanelli, MelissaCappuzzo, FedericoAerts, Joachim G. J., VGiusti, RaffaeleBria, EmilioCortinovis, DiegoGrossi, FrancescoMigliorino, Maria R.Galetta, DomenicoPassiglia, FrancescoBerardi, RossanaMazzoni, FrancescaDi Noia, VincenzoSignorelli, DiegoTuzi, AlessandroGelibter, AlainMarchetti, PaoloMacerelli, MariannaRastelli, FrancescaChiari, RitaRocco, DaniloInno, AlessandroDi Marino, PietroMansueto, GiovanniZoratto, FedericaSantoni, MatteoTudini, MariannaGhidini, MicheleFiletti, MarcoCatino, AnnamariaPizzutilo, PamelaSala, LucaOcchipinti, Mario AlbertoCitarella, FabrizioMarco, RussanoTorniai, MariangelaCantini, LucaFollador, AlessandroSforza, VincenzoNigro, OlgaFerrara, Miriam G.D'Argento, EttoreLeonetti, AlessandroPettoruti, LindaAntonuzzo, LorenzoScodes, Simona
- [27] Immunotherapy for PDL1-high (TPS≥50%) metastatic NSCLC: Results in real-world oncology practiceANNALS OF ONCOLOGY, 2021, 32 : S1015 - S1015Srdic, D.Bitar, L.Seiwerth, F.Gabaj, N. NikolacMarusic, A.Vuletic, L. BateljaBadovinac, S.Plestina, S.Samarzija, M.Jakopovic, M.
- [28] Real-World Prevalence of PD-L1 Expression in Chinese Patients with Advanced or Metastatic NSCLC: Express II StudyJOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S410 - S410Lin, D.Yang, X.Jiang, L.Wang, W.Hou, Y.Li, Y.Jin, Y.Fan, X.Sun, W.Yun, J.Li, P.Kuang, D.Zhang, L.Ni, J.Mao, A.Tang, W.Liu, Z.Wang, J.Xiao, S.
- [29] Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS ≥50%JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S389 - S390Frost, N.Ghori, R.Roy, A.Nunes, A. T.Yang, J. C. -H.
- [30] Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyEUROPEAN JOURNAL OF CANCER, 2021, 148 : 24 - 35Cortellini, AlessioCannita, KatiaTiseo, MarcelloCortinovis, Diego L.Aerts, Joachim G. J., VBaldessari, CinziaGiusti, RaffaeleFerrara, Miriam G.D'Argento, EttoreGrossi, FrancescoGuida, AnnalisaBerardi, RossanaMorabito, AlessandroGenova, CarloAntonuzzo, LorenzoMazzoni, FrancescaDe Toma, AlessandroSignorelli, DiegoGelibter, AlainTargato, GiadaRastelli, FrancescaChiari, RitaRocco, DaniloGori, StefaniaDe Tursi, MicheleMansueto, GiovanniZoratto, FedericaFiletti, MarcoBracarda, SergioCitarella, FabrizioRussano, MarcoCantini, LucaNigro, OlgaButi, SebastianoMinuti, GabrieleLandi, LorenzaRicciardi, SerenaMigliorino, Maria R.Natalizio, SalvatoreSimona, CarnioDe Filippis, MarcoMetro, GiulioAdamo, VincenzoRusso, AlessandroSpinelli, Gian P.Di Maio, MassimoBanna, Giuseppe L.Friedlaender, AlexAddeo, AlfredoPinato, David J.